Carboxymethyl high amylose starch: Chitosan self-stabilized matrix for probiotic colon delivery

被引:42
作者
Calinescu, Carmen
Mateescu, Mircea Alexandru [1 ]
机构
[1] Univ Quebec, Dept Chem, Montreal, PQ H3C 3P8, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Carboxymethyl high amylose starch; Chitosan; Tablet; Lactobacillus rhamnosus probiotic; Colon delivery;
D O I
10.1016/j.ejpb.2008.06.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A new hydrophilic tablet dosage system based on an ionic self-stabilization of a carboxylated (carboxymethyl high amylose starch, CM-HAS) and an amino (Chitosan) excipient was proposed for probiotic colon delivery. CM-HAS (protonated and compacted in acidic medium) ensures gastro-protection and Chitosan (low soluble in intestinal media) prevents early release of Lactobacillus rhamnosus bacteria. Thus, in CM-HAS:Chitosan monolithic tablets, increasing percentage and molecular weight (MW) of Chitosan generated a decrease of bacteria release rate, bacteria being the most effectively retarded by the highest MW of Chitosan (2.2 x 10(6) g/mol). The monolithic formulations containing high percentages of CM-HAS (80%) delivered bacteria after 2 h of incubation in gastrointestinal conditions for all the Chitosan MWs used. A combined mechanism of bacteria release is proposed for CM-HAS:Chitosan monolithic tablets, involving the swelling of the tablets (due to the Chitosan), followed by the erosion and dissolution of CM-HAS. In addition, a gel-forming barrier of Chitosan in acidic conditions also contributed to the delay of the bacteria delivery. The CM-HAS dry-coated monolithic tablets changed the effect of Chitosan molecular weight on bacteria liberation and improved the percentage of delivered bacteria in simulated intestinal conditions. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:582 / 589
页数:8
相关论文
共 29 条
[21]   CHARACTERIZATION OF CHITOSAN - INFLUENCE OF IONIC-STRENGTH AND DEGREE OF ACETYLATION ON CHAIN EXPANSION [J].
RINAUDO, M ;
MILAS, M ;
LEDUNG, P .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 1993, 15 (05) :281-285
[22]  
Sabnis S, 1997, Pharm Dev Technol, V2, P243, DOI 10.3109/10837459709031444
[23]   In vitro evaluation of microcrystalline chitosan (MCCh) as gel-forming excipient in matrix granules [J].
Säkkinen, M ;
Seppälä, U ;
Heinänen, P ;
Marvola, M .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2002, 54 (01) :33-40
[24]   Immune modulation of blood leukocytes in humans by lactic acid bacteria: Criteria for strain selection [J].
Schiffrin, EJ ;
Brassart, D ;
Servin, AL ;
Rochat, F ;
DonnetHughes, A .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1997, 66 (02) :515-520
[25]  
The United States Pharmacopeial Convention Inc, 2000, US PHARM NAT FORM US
[26]   Chitosan capsules for colon-specific drug delivery: Improvement of insulin absorption from the rat colon [J].
Tozaki, H ;
Komoike, J ;
Tada, C ;
Maruyama, T ;
Terabe, A ;
Suzuki, T ;
Yamamoto, A ;
Muranishi, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (09) :1016-1021
[27]   DETERMINATION OF THE MARK-HOUWINK EQUATION FOR CHITOSANS WITH DIFFERENT DEGREES OF DEACETYLATION [J].
WEI, W ;
BO, SQ ;
LI, SQ ;
WEN, Q .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 1991, 13 (05) :281-285
[28]   EFFECT OF CHITOSAN ON MEMBRANE-PERMEABILITY OF SUSPENSION-CULTURED GLYCINE-MAX AND PHASEOLUS-VULGARIS CELLS [J].
YOUNG, DH ;
KOHLE, H ;
KAUSS, H .
PLANT PHYSIOLOGY, 1982, 70 (05) :1449-1454
[29]   In vitro degradation of chitosan by bacterial enzymes from rat cecal and colonic contents [J].
Zhang, H ;
Neau, SH .
BIOMATERIALS, 2002, 23 (13) :2761-2766